HRP20211539T1 - Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson - Google Patents
Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson Download PDFInfo
- Publication number
- HRP20211539T1 HRP20211539T1 HRP20211539TT HRP20211539T HRP20211539T1 HR P20211539 T1 HRP20211539 T1 HR P20211539T1 HR P20211539T T HRP20211539T T HR P20211539TT HR P20211539 T HRP20211539 T HR P20211539T HR P20211539 T1 HRP20211539 T1 HR P20211539T1
- Authority
- HR
- Croatia
- Prior art keywords
- acid
- tablet
- buprenorphine
- particles
- naloxone
- Prior art date
Links
- SFNLWIKOKQVFPB-KZCPYJDTSA-N bunavail Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C.C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 SFNLWIKOKQVFPB-KZCPYJDTSA-N 0.000 title 1
- 239000002245 particle Substances 0.000 claims 7
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 6
- 229960001736 buprenorphine Drugs 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 239000011859 microparticle Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000011521 glass Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 3
- 229960004127 naloxone Drugs 0.000 claims 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 235000011054 acetic acid Nutrition 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000001361 adipic acid Substances 0.000 claims 1
- 235000011037 adipic acid Nutrition 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 235000006408 oxalic acid Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000008057 potassium phosphate buffer Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (8)
1. Tableta pogodna za sublingvalno davanje koja sadrži:
(a) mikročestice farmakološki-efikasne količine buprenorfina, ili njegove farmaceutski prihvatljive soli;
(b) čestice slabe kiseline;
(c) čestice farmakološki-efikasne količine naloksona, ili njegove farmaceutski prihvatljive soli;
(d) dozni odnos buprenorfin:nalokson od 4:1 (±10%; izračunato kao slobodne baze); i
(e) dezintegrant,
pri čemu, kada je pH izmjerena kapanjem vodene otopineUSP/NF kalijevog fosfatnog pufera sa pH od 6.8 u brzini od 2 mL po minuti kroz cjevčicu s unutrašnjim promjerom od 3 mm na navedenu tabletu postavljenu na vrh poroznog filtera od silicijevog dioksida promjera 1 20 mm u staklenom lijevku sa gornjim unutrašnjim promjerom od 55 mm, u kojem je udaljenost između kraja cjevčice i filtera od silicijevog dioksida u lijevku 7.5 cm, i pH je izmjerena na izlazu iz staklenog lijevka, tableta prikazuje:
(i) maksimalni pad pH od 6.8 između 0.5 do 5 pH jedinica u 1 minutu (±10%); nakon čega slijedi
(ii) vraćanje na početnu pH (±0.5) tokom 3 minute (±10%),
sa pH padom i povećanjem koje je mjereno sa početkom kapanja iz izlaza staklenog lijevka.
2. Tableta prema zahtjevu 1 gdje je doza buprenorfina 11.4 mg, 8.6 mg, 5.7 mg, 2.9 mg ili 1.4 mg; i doza naloksona je 2.9 mg, 2.2 mg, 1.4 mg, 0.7 mg i 0.4 mg, redom.
3. Tableta kao što je navedeno u bilo kojem od prethodnih zahtjeva, u kojoj su mikročestice buprenorfina ili njegove soli su asocijativno pomiješane zajedno sa česticama slabe kiseline.
4. Tableta prema zahtjevu 3, pri čemu smjesa sadrži mješavinu mikročestica buprenorfina, ili njegove soli, zajedno sa česticama slabe kiseline.
5. Tableta kao što je navedeno u bilo kojem od prethodnih zahtjeva, gdje slab kiselinski materijal sadrži limunsku kiselinu, vinsku kiselinu, jabučnu kiselinu, fumarnu kiselinu, adipinsku kiselinu, sukcinsku kiselinu, mliječnu kiselinu, octenu kiselinu, oksalnu kiselinu, maleinsku kiselinu, amonijev klorid ili njihovu kombinaciju.
6. Tableta kao što je navedeno u bilo kojem od prethodnih zahtjeva, u kojoj su mikročestice buprenorfina ili njegove farmaceutski prihvatljive soli su vezane za, pričvršćene za, ili povezane sa, površinama većih čestica nosača.
7. Tableta prema zahtjevima 6 u kojoj su prisutne spomenute čestice slabe kiseline, bar dijelom, na površinama, i/ili između, spomenutih čestica nosača.
8. Tableta kao što je navedeno u bilo kojem od prethodnih zahtjeva, pri čemu je dezintegrant izabran iz grupe kroskarmeloza natrij, natrijskrobglikolat, umreženog polivinilpirolidona i njihovih mješavina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161536180P | 2011-09-19 | 2011-09-19 | |
EP15156024.0A EP2915525B1 (en) | 2011-09-19 | 2012-09-18 | Sublingual abuse-resistant tablets comprising buprenorphine and naloxone |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211539T1 true HRP20211539T1 (hr) | 2021-12-24 |
Family
ID=47046639
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211539TT HRP20211539T1 (hr) | 2011-09-19 | 2012-09-18 | Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson |
HRP20150369TT HRP20150369T1 (hr) | 2011-09-19 | 2015-03-30 | Novi farmaceutski pripravak otporan na zlouporabu za tretiranje zavisnosti o opioidima |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150369TT HRP20150369T1 (hr) | 2011-09-19 | 2015-03-30 | Novi farmaceutski pripravak otporan na zlouporabu za tretiranje zavisnosti o opioidima |
Country Status (31)
Country | Link |
---|---|
US (15) | US8940330B2 (hr) |
EP (3) | EP2706986B1 (hr) |
JP (2) | JP6210988B2 (hr) |
KR (1) | KR102078044B1 (hr) |
CN (1) | CN103813785B (hr) |
AU (1) | AU2012311293B2 (hr) |
BR (1) | BR112014006356B1 (hr) |
CA (1) | CA2834327C (hr) |
CL (1) | CL2014000575A1 (hr) |
CO (1) | CO6960541A2 (hr) |
CY (2) | CY1116270T1 (hr) |
DK (2) | DK2915525T3 (hr) |
EA (1) | EA029507B1 (hr) |
ES (2) | ES2887104T3 (hr) |
HK (2) | HK1193568A1 (hr) |
HR (2) | HRP20211539T1 (hr) |
HU (1) | HUE056309T2 (hr) |
IL (1) | IL230528B (hr) |
LT (1) | LT2915525T (hr) |
ME (1) | ME02153B (hr) |
MX (1) | MX361757B (hr) |
MY (1) | MY185284A (hr) |
PE (1) | PE20141198A1 (hr) |
PL (2) | PL2706986T3 (hr) |
PT (2) | PT2706986E (hr) |
RS (2) | RS62505B1 (hr) |
SG (1) | SG2014009401A (hr) |
SI (2) | SI2706986T1 (hr) |
SM (1) | SMT201500126B (hr) |
WO (1) | WO2013041851A1 (hr) |
ZA (1) | ZA201400501B (hr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012311293B2 (en) | 2011-09-19 | 2014-02-20 | Orexo Ab | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
US20140280531A1 (en) * | 2013-03-13 | 2014-09-18 | Xin Liu | Object ranking and recommendations within a social network |
EP2983668A4 (en) * | 2013-04-08 | 2017-01-11 | Virginia Commonwealth University | Compositions to alleviate presystemic metabolism of opioids |
EP2886103A1 (en) * | 2013-12-23 | 2015-06-24 | Hexal AG | Pharmaceutical orodispersible film comprising buprenorphine particles with a particular size |
US10617686B2 (en) * | 2014-07-08 | 2020-04-14 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
US10722510B2 (en) | 2014-07-08 | 2020-07-28 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
EP3177146A4 (en) * | 2014-07-08 | 2018-01-03 | Insys Pharma, Inc. | Sublingual naloxone spray |
US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
NZ731309A (en) | 2014-11-07 | 2022-02-25 | Indivior Uk Ltd | Buprenorphine dosing regimens |
WO2018034920A1 (en) * | 2016-08-17 | 2018-02-22 | Insys Development Company, Inc. | Liquid naloxone spray |
CN110325178B (zh) * | 2016-12-26 | 2022-05-13 | 盐野义制药株式会社 | 改善含量均一性的制剂的制造方法 |
US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
WO2019064026A1 (en) | 2017-09-29 | 2019-04-04 | Orexo Ab | NEW PHARMACEUTICAL COMPOSITIONS |
BR112020007808A2 (pt) * | 2017-10-20 | 2020-10-20 | Chiesi Farmaceutici S.P.A. | formulações farmacêuticas que compreendem um agonista de receptor de opioide como ingrediente ativo, métodos de fabricação e usos terapêuticos destas |
CN111479592B (zh) * | 2017-11-15 | 2023-05-26 | 加利福尼亚大学董事会 | 阿片样物质使用障碍、阿片样物质戒断症状和慢性疼痛的治疗 |
AU2019236389A1 (en) | 2018-03-11 | 2020-07-30 | Nanologica Ab | Porous silica particles for use in compressed pharmaceutical dosage form |
GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
KR20220003541A (ko) * | 2019-04-18 | 2022-01-10 | 키에시 파르마슈티시 엣스. 피. 에이. | 신생아 오피오이드 금단 증후군 치료를 위한 방법 |
US11571414B2 (en) | 2019-09-06 | 2023-02-07 | Eric Dwayne Ford | Methods of treating respiratory illnesses, alleviating inflammation and visceral pain, and alleviating opioid addiction while suppressing withdrawal symptoms |
MX2022010800A (es) * | 2020-03-11 | 2022-09-27 | Purdue Pharma Lp | Composiciones y metodos para la administracion de naloxona. |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1428361A (en) | 1972-02-15 | 1976-03-17 | Grant A | Safeguarded medicinal compositions |
JPS5138412A (en) | 1974-09-24 | 1976-03-31 | Nippon Kayaku Kk | Kokoseizai no seiho |
US4175119A (en) | 1978-01-11 | 1979-11-20 | Porter Garry L | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs |
US4457933A (en) | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
AU8533582A (en) | 1981-07-10 | 1984-01-12 | Reckitt & Colman Products Limited | Stable solutions of buprenorphine |
US4459278A (en) | 1983-03-07 | 1984-07-10 | Clear Lake Development Group | Composition and method of immobilizing emetics and method of treating human beings with emetics |
US4529583A (en) | 1983-03-07 | 1985-07-16 | Clear Lake Development Group | Composition and method of immobilizing emetics and method of treating human beings with emetics |
GB8332556D0 (en) | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
FR2562313B1 (fr) | 1984-04-03 | 1989-04-07 | Cogema | Procede de decontamination en uranium et en radium de solutions uraniferes acides par addition d'un sel d'aluminium |
GB2162061B (en) | 1984-05-03 | 1988-11-16 | Bibhuti B Bardhan | Controlled time release therapeutic composition having means for counteracting overdosage |
GB8430346D0 (en) | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4885173A (en) | 1985-05-01 | 1989-12-05 | University Of Utah | Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities |
US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
FR2582513B1 (fr) | 1985-05-28 | 1988-08-05 | Synthelabo | Compositions pharmaceutiques contenant de l'alfuzosine |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
GB8728294D0 (en) | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
SE8800080L (sv) | 1988-01-13 | 1989-07-14 | Kabivitrum Ab | Laekemedelskomposition |
US4981468A (en) | 1989-02-17 | 1991-01-01 | Eli Lilly And Company | Delivery device for orally administered therapeutic agents |
US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
CA2070061C (en) | 1991-06-07 | 2004-02-10 | Shigeyuki Takama | Physiologically active polypeptide-containing pharmaceutical composition |
US5192802A (en) | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
US5362496A (en) | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
US5547878A (en) | 1993-11-02 | 1996-08-20 | Kell; Michael | Method of monitoring patient compliance with medications prescriptions |
US5856493A (en) | 1995-02-06 | 1999-01-05 | Smithkline Beecham Corporation | Process for making novel form of paroxeting hydrochloride anhydrate |
US5888534A (en) | 1995-06-13 | 1999-03-30 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
PT914097E (pt) | 1996-03-12 | 2002-06-28 | Alza Corp | Composicao e forma de dosagem compreendendo antagonista de opioide |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
JP2000505090A (ja) | 1996-07-11 | 2000-04-25 | ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ | インドール選択的セロトニンアゴニストを含む包接錯体 |
US6217000B1 (en) | 1996-10-25 | 2001-04-17 | The Boeing Company | Composite fabrication method and tooling to improve part consolidation |
GB9710726D0 (en) | 1997-05-23 | 1997-07-16 | Nycomed Imaging As | Compound |
WO1998053802A1 (en) | 1997-05-30 | 1998-12-03 | Laboratorios Phoenix U.S.A., Inc. | Multi-layered osmotic device |
WO1999032120A1 (en) | 1997-12-22 | 1999-07-01 | Euro-Celtique, S.A. | A method of preventing abuse of opioid dosage forms |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
ES2138937B1 (es) | 1998-07-07 | 2000-10-01 | Medichem Sa | Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen. |
SE9803239D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
SE9803240D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
IT1302682B1 (it) | 1998-10-16 | 2000-09-29 | Formenti Farmaceutici Spa | Composizioni farmaceutiche orali contenenti buprenorfina |
US6228469B1 (en) | 1999-09-07 | 2001-05-08 | Corning Incorporated | Protective coating on metal |
US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
AR031682A1 (es) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
BRPI0108380B8 (pt) | 2000-02-08 | 2021-05-25 | Euro Celtique S/A | fórmulas de opióides agonistas resistentes à adulteração, método para diminuir o abuso de um opióide agonista numa fórmula de dosagem oral, método de preparação de uma fórmula de dosagem oral e método de tratamento da dor |
EP1274444B1 (en) | 2000-03-16 | 2013-05-15 | THE McLEAN HOSPITAL CORPORATION | Cdp-choline and uridine for the treatment of alcohol abuse |
GB0026137D0 (en) | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
US20020160043A1 (en) | 2001-02-27 | 2002-10-31 | Dennis Coleman | Compositions and method of manufacture for oral dissolvable dosage forms |
US6897123B2 (en) | 2001-03-05 | 2005-05-24 | Agityne Corporation | Bonding of parts with dissimilar thermal expansion coefficients |
WO2002092060A1 (en) | 2001-05-11 | 2002-11-21 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
US20030004177A1 (en) | 2001-05-11 | 2003-01-02 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
US20030035839A1 (en) | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
US20030068356A1 (en) | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
DK1416842T3 (da) | 2001-07-18 | 2009-03-16 | Euro Celtique Sa | Farmaceutiske kombinationer af oxycodon og naloxon |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US7144587B2 (en) | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
US20110033542A1 (en) * | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
CA2464528A1 (en) | 2001-11-02 | 2003-05-15 | Elan Corporation, Plc | Pharmaceutical composition |
US6472563B1 (en) | 2001-11-09 | 2002-10-29 | Sepracor Inc. | Formoterol tartrate process and polymorph |
US6974818B2 (en) | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
US20030191147A1 (en) | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
WO2004054511A2 (en) | 2002-12-13 | 2004-07-01 | The Regents Of The University Of California | Analgesic combination comprising nalbuphine |
US7524515B2 (en) | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
AU2004208644B2 (en) | 2003-01-31 | 2009-07-23 | Orexo Ab | A rapid-acting pharmaceutical composition |
US8512727B2 (en) * | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
US20050042281A1 (en) | 2003-08-21 | 2005-02-24 | Singh Nikhilesh N. | Compositions for delivering therapeutic agents across the oral mucosa |
EP1750675B1 (en) * | 2004-06-02 | 2008-10-29 | Galephar M/F | Stable oral pharmaceutical compositions of buprenorphine and salt thereof |
US20060051413A1 (en) | 2004-09-08 | 2006-03-09 | Chow Sing S M | Method of enhancing absorptions of transmucosal administration formulations |
FR2883179B1 (fr) | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
MX2007011977A (es) | 2005-03-28 | 2007-12-07 | Orexo Ab | Composiciones farmaceuticas novedosas utiles en el tratamiento del dolor. |
US8021638B2 (en) | 2005-03-31 | 2011-09-20 | Touchstone Research Laboratory, Ltd | Carbon foam and high density carbon foam composite tooling |
US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
JP2007321063A (ja) * | 2006-06-01 | 2007-12-13 | Sumitomo Chemical Co Ltd | 樹脂粒子の分離方法 |
US20100233257A1 (en) * | 2006-06-09 | 2010-09-16 | Ethypharm | Low dose sublingual tablets of opioid analgesics and preparation process |
US20070286900A1 (en) | 2006-06-09 | 2007-12-13 | Catherine Herry | Low dose tablets of opioid analgesics and preparation process |
RS54764B1 (sr) | 2006-07-21 | 2016-10-31 | Biodelivery Sciences Int Inc | Sredstvo za transmukozalnu isporuku sa povećanim nakupljanjem |
EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
CN1943575A (zh) | 2006-10-24 | 2007-04-11 | 岳振江 | 滥用潜力低的复方盐酸丁丙诺啡盐酸纳洛酮舌下片 |
DK2101740T3 (da) * | 2006-12-04 | 2013-11-18 | Orexo Ab | Nye ikke-misbrugs-farmaceutiske sammensætninger omfattende opioider |
GB2447016A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Buprenorphine/naloxone compositions |
GB2447015A (en) | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
US20100098757A1 (en) | 2007-03-15 | 2010-04-22 | Toyo Boseki Kabushiki Kaisha | Process for production of buprenorphine pharmaceutical preparation to be applied to mouth mucosa |
GB2450117A (en) * | 2007-06-13 | 2008-12-17 | Reckitt Benckiser Healthcare | A water- and oxygen-occlusive blister tablet pack |
GB0712535D0 (en) | 2007-06-28 | 2007-08-08 | Airbus Uk Ltd | Method for forming composite components and tool for use therein |
US7968021B2 (en) | 2007-07-31 | 2011-06-28 | The Boeing Company | Coefficient of thermal expansion control structure |
US20090263476A1 (en) | 2008-04-16 | 2009-10-22 | Jobdevairakkam Christopher N | Composition of Rapid Disintegrating Direct Compression Buccal Tablet |
US20090266870A1 (en) | 2008-04-23 | 2009-10-29 | The Boeing Company | Joined composite structures with a graded coefficient of thermal expansion for extreme environment applications |
JP2010043236A (ja) * | 2008-07-17 | 2010-02-25 | Sekisui Chem Co Ltd | タンニン系接着剤、及びそれを用いた木質系複合材料 |
JP2012526840A (ja) | 2009-05-13 | 2012-11-01 | プロテイン デリヴァリー ソリューションズ エルエルシー | 膜貫通送達のための製剤系 |
US8475832B2 (en) * | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
US8269514B2 (en) | 2009-08-25 | 2012-09-18 | Formfactor, Inc. | Method and apparatus for multilayer support substrate |
JP5371050B2 (ja) * | 2009-11-06 | 2013-12-18 | 住友精化株式会社 | ジボランの製造方法 |
AU2012311293B2 (en) | 2011-09-19 | 2014-02-20 | Orexo Ab | New abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
AU2013255640B2 (en) | 2012-05-02 | 2017-06-15 | Orexo Ab | New alfentanil composition for the treatment of acute pain |
-
2012
- 2012-09-18 AU AU2012311293A patent/AU2012311293B2/en active Active
- 2012-09-18 PT PT127752830T patent/PT2706986E/pt unknown
- 2012-09-18 ME MEP-2015-71A patent/ME02153B/me unknown
- 2012-09-18 KR KR1020147006990A patent/KR102078044B1/ko active IP Right Grant
- 2012-09-18 JP JP2014530322A patent/JP6210988B2/ja active Active
- 2012-09-18 EP EP12775283.0A patent/EP2706986B1/en active Active
- 2012-09-18 MY MYPI2014000778A patent/MY185284A/en unknown
- 2012-09-18 EP EP21190278.8A patent/EP3939569A1/en active Pending
- 2012-09-18 DK DK15156024.0T patent/DK2915525T3/da active
- 2012-09-18 PL PL12775283T patent/PL2706986T3/pl unknown
- 2012-09-18 SG SG2014009401A patent/SG2014009401A/en unknown
- 2012-09-18 HU HUE15156024A patent/HUE056309T2/hu unknown
- 2012-09-18 EA EA201400246A patent/EA029507B1/ru unknown
- 2012-09-18 WO PCT/GB2012/052303 patent/WO2013041851A1/en active Application Filing
- 2012-09-18 ES ES15156024T patent/ES2887104T3/es active Active
- 2012-09-18 RS RS20211282A patent/RS62505B1/sr unknown
- 2012-09-18 EP EP15156024.0A patent/EP2915525B1/en active Active
- 2012-09-18 MX MX2014002556A patent/MX361757B/es active IP Right Grant
- 2012-09-18 LT LTEP15156024.0T patent/LT2915525T/lt unknown
- 2012-09-18 PE PE2014000336A patent/PE20141198A1/es active IP Right Grant
- 2012-09-18 DK DK12775283.0T patent/DK2706986T3/en active
- 2012-09-18 US US14/127,470 patent/US8940330B2/en active Active
- 2012-09-18 BR BR112014006356-7A patent/BR112014006356B1/pt active IP Right Grant
- 2012-09-18 RS RS20150299A patent/RS53995B1/en unknown
- 2012-09-18 PL PL15156024T patent/PL2915525T3/pl unknown
- 2012-09-18 SI SI201230188T patent/SI2706986T1/sl unknown
- 2012-09-18 HR HRP20211539TT patent/HRP20211539T1/hr unknown
- 2012-09-18 SI SI201231949T patent/SI2915525T1/sl unknown
- 2012-09-18 CN CN201280045350.9A patent/CN103813785B/zh active Active
- 2012-09-18 PT PT151560240T patent/PT2915525T/pt unknown
- 2012-09-18 CA CA2834327A patent/CA2834327C/en active Active
- 2012-09-18 US US13/622,151 patent/US20130071477A1/en not_active Abandoned
- 2012-09-18 ES ES12775283.0T patent/ES2538460T3/es active Active
-
2013
- 2013-03-13 US US13/802,292 patent/US20140023704A1/en not_active Abandoned
-
2014
- 2014-01-19 IL IL230528A patent/IL230528B/en active IP Right Grant
- 2014-01-22 ZA ZA2014/00501A patent/ZA201400501B/en unknown
- 2014-03-04 CO CO14045641A patent/CO6960541A2/es unknown
- 2014-03-10 CL CL2014000575A patent/CL2014000575A1/es unknown
- 2014-07-09 HK HK14106999.2A patent/HK1193568A1/xx unknown
- 2014-12-19 US US14/577,823 patent/US9439900B2/en active Active
-
2015
- 2015-03-25 US US14/668,973 patent/US9259421B2/en active Active
- 2015-03-30 HR HRP20150369TT patent/HRP20150369T1/hr unknown
- 2015-04-29 US US14/699,889 patent/US20150238482A1/en not_active Abandoned
- 2015-05-13 CY CY20151100422T patent/CY1116270T1/el unknown
- 2015-05-28 SM SM201500126T patent/SMT201500126B/xx unknown
- 2015-11-17 HK HK15111331.8A patent/HK1210438A1/xx unknown
-
2016
- 2016-09-09 US US15/261,571 patent/US20160375010A1/en not_active Abandoned
- 2016-11-18 US US15/355,140 patent/US20170246161A1/en not_active Abandoned
-
2017
- 2017-04-27 US US15/499,645 patent/US20180042920A1/en not_active Abandoned
- 2017-05-31 US US15/609,374 patent/US20180104235A1/en not_active Abandoned
- 2017-07-04 JP JP2017131077A patent/JP2017171687A/ja not_active Withdrawn
-
2018
- 2018-07-31 US US16/050,592 patent/US10874661B2/en active Active
-
2020
- 2020-09-01 US US17/009,702 patent/US10946010B2/en active Active
- 2020-09-25 US US17/033,019 patent/US11020388B2/en active Active
- 2020-09-25 US US17/032,934 patent/US11020387B2/en active Active
- 2020-09-25 US US17/032,882 patent/US11433066B2/en active Active
-
2021
- 2021-10-19 CY CY20211100911T patent/CY1124764T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211539T1 (hr) | Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson | |
HRP20161277T1 (hr) | Pripravci za liječenje centralno posredovane mučnine i povraćanja | |
HRP20160327T1 (hr) | Čvrsti dozirni oblici fentanila s poboljšanom bukalnom apsorpcijom | |
JP2013535505A5 (hr) | ||
MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
HRP20110049T2 (hr) | Opioidi za liječenje nemirnosti kod donjih ekstremiteta | |
MX2010000856A (es) | Composicion farmaceutica que contiene un antagonista del canal de calcio de tipo dihidropiridina y metodo para la preparacion de la misma. | |
JP2009143964A5 (hr) | ||
NZ604417A (en) | Liquid nasal spray containing low-dose naltrexone | |
MX2013013276A (es) | Formas de dosificacion farmaceuticas intranasales que comprenden naloxona. | |
HRP20121033T1 (hr) | Praškasta formulacija za valganciklovir | |
JP2012193216A5 (hr) | ||
RU2013136350A (ru) | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист | |
MX347135B (es) | Composición farmacéutica de sabor enmascarado para administración oral, y proceso para la preparación de la misma. | |
CA2671954A1 (en) | Methods for treating or preventing symptoms of hormonal variations | |
WO2008067399A3 (en) | Controlled-release multi-layer formulation of piperazine-piperidine antagonists and agonists of the 5-th1a receptor having enhanced intestinal dissolution | |
HRP20180018T1 (hr) | Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja | |
IL198314A (en) | History of Quinuclidine of (hetero) Acrylic Cyclohepethecarboxylic Acid, Process of Preparation, Medicinal Preparations Containing Them and Use of Drug Preparation for Treatment | |
JP2016527220A5 (hr) | ||
HRP20201736T1 (hr) | Postupak liječenja diskinezije | |
HRP20100373T4 (hr) | Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima | |
EP2796450A4 (en) | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES | |
ATE542525T1 (de) | Verbesserte pharmazeutische zusammensetzung mit einem pyrrolidon-antikonvulsivum und verfahren zu seiner herstellung | |
HRP20161529T1 (hr) | Spoj benzazepina |